Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a promising development for weight loss . Initial human tests have indicated considerable decreases in abdominal mass , conceivably exceeding other body composition medications . However , more evaluati